Genome Medicine (Mar 2022)

DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors

  • Tincy Simon,
  • Pamela Riemer,
  • Armin Jarosch,
  • Katharina Detjen,
  • Annunziata Di Domenico,
  • Felix Bormann,
  • Andrea Menne,
  • Slim Khouja,
  • Nanna Monjé,
  • Liam H. Childs,
  • Dido Lenze,
  • Ulf Leser,
  • Florian Rossner,
  • Markus Morkel,
  • Nils Blüthgen,
  • Marianne Pavel,
  • David Horst,
  • David Capper,
  • Ilaria Marinoni,
  • Aurel Perren,
  • Soulafa Mamlouk,
  • Christine Sers

DOI
https://doi.org/10.1186/s13073-022-01018-w
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background Pancreatic neuroendocrine neoplasms (PanNENs) fall into two subclasses: the well-differentiated, low- to high-grade pancreatic neuroendocrine tumors (PanNETs), and the poorly-differentiated, high-grade pancreatic neuroendocrine carcinomas (PanNECs). While recent studies suggest an endocrine descent of PanNETs, the origin of PanNECs remains unknown. Methods We performed DNA methylation analysis for 57 PanNEN samples and found that distinct methylation profiles separated PanNENs into two major groups, clearly distinguishing high-grade PanNECs from other PanNETs including high-grade NETG3. DNA alterations and immunohistochemistry of cell-type markers PDX1, ARX, and SOX9 were utilized to further characterize PanNECs and their cell of origin in the pancreas. Results Phylo-epigenetic and cell-type signature features derived from alpha, beta, acinar, and ductal adult cells suggest an exocrine cell of origin for PanNECs, thus separating them in cell lineage from other PanNENs of endocrine origin. Conclusions Our study provides a robust and clinically applicable method to clearly distinguish PanNECs from G3 PanNETs, improving patient stratification.

Keywords